Monday, June 7, 2004, including Plenary Sessions

For those users interested in obtaining CME for this program, please enter the CME portion of this course. To receive CME for each day, you must view all reports and fax the required documentation at the conclusion of the reviews.

In order to print the required documentation, you will need Adobe Reader, which is available for free on the Adobe Website.

OncoLink's ASCO Coverage made possible by an unrestricted Educational Grant from Bristol-Myers Squibb Oncology.

A historical perspective on the American Society of Clinical Oncology (ASCO) In April 1964 seven visionary doctors met for lunch at the Edgewater Bridge Hotel in Chicago. They had this novel idea to of gathering together all physicians treating patients with cancer and sharing their experiences as well as information. There...
A multicenter phase III comparison of docetaxel + prednisone and mitoxantrone + prednisone in patients with hormone-refractory prostate cancer This article discusses non-FDA approved dosing of docetaxel Presenter: M.A. EisenbergerPresenter's Affiliation: TAX-327 InvestigatorsType of Session: PlenaryBackground Therapy for metastatic hormone-refractory prostate cancer (HRPC) has...
A multicenter, phase III randomized trial for stage IIIb/IV NSCLC of weekly paclitaxel and carboplatin vs. standard paclitaxel and carboplatin given every three weeks, followed by weekly paclitaxel This presentation discusses unapproved dosing schedules for carboplatin and paclitaxel. Presenter: C. P. BelaniPresenter's Affiliation: University of Pittsburg Cancer Institute, Pittsburg, PAType of Session: ScientificBackground Previous trials...
A randomized comparison of single agent carboplatin with radiotherapy in the adjuvant treatment of stage I seminoma of the testis following orchiectomy: MRC TE19/EORTC 30982 This presentation discusses off-label use of carboplatin in the treatment of seminoma. Presenter: R.T. OliverPresenter's Affiliation: Medical Research Counsel, EnglandType of Session: ScientificBackground Adjuvant radiation therapy (RT) is an...
Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a radomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. Presenter: R. StuppPresenter's Affiliation: University Hospital (CHUV), Lausanne, SwitzerlandType of Session: PlenaryBackground Glioblastoma multiforme is the most malignant and most common primary brain tumor, with a dismal median overall survival...
Eliminating the Suffering and Death from Cancer: A Cancer Center Director's Experience New this year at ASCO is a plenary science presentation. To mark the beginning of this tradition Dr. Leland H. Harwell was chosen for this honorable task. Dr. Harwell won a Nobel Prize in medicine in 2001 for his work in yeast genetics. He is...
Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126 This presentation discusses off-label use of gefitinib in BAC. Presenter: H. WestPresenter's Affiliation: Swedish Cancer Institute, Seattle, WAType of Session: ScientificBackground Bronchioloalveolar lung cancer (BAC) is a distinctive subtype of...
HMG CoA reductase inhibitors and the risk of colorectal cancer This article discusses non-FDA approved uses of simvastatin and pravastatin Presenter: J. N. PoynterPresenter's Affiliation: University of Michigan, Ann Arbor, MIType of Session: PlenaryBackground In vitro data have shown that...
Long-term effects of conservation therapy for muscle invasive bladder carcinoma Presenter: P. ChungPresenter's Affiliation: Princess Margaret Hospital, Toronto, ON, CanadaType of Session: ScientificBackground Cystectomy has long been considered the gold standard for treatment of muscle invasive bladder carcinoma. This...
Preliminary evidence of relationship between genetic markers and oncology patient quality of life Presenter: J.A. SloanPresenter's Affiliation: The North Central Cancer Treatment GroupType of Session: PlenaryBackground Genetic variation has been linked to a number of factors that affect quality of life (QOL) including depression, suicide,...
Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC) : 'the "LUCAS" study This presentation discusses off-label use of cetuximab in the treatment of NSCLC. Presenter: R. RosellPresenter's Affiliation: Institut Catala d'Oncologia, Barcelona, SpainType of Session: ScientificBackground The advent of molecular therapeutics...
Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) This presentation discusses the use of erlotinib for the treatment of NSCLC which has not been approved by the FDA. Presenter: U. GatzemeierPresenter's Affiliation: TALENT study investigatorsType of Session: ScientificBackground There is a growing...
Risk-adapted management of stage I seminoma: the second Spanish Germ Cell Cancer Group (GG) study * This presentation discusses off-label use of carboplatin in the treatment of seminoma. Presenter: J. AparicioPresenter's Affiliation: Spanish Germ Cell Cancer GroupType of Session: ScientificBackground Seminoma represents 45% of all germ cell...
SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone (M)/prednisone (P) in men with androgen-independent prostate cancer (AIPCA) Presenter: D.P. PetrylakPresenter's Affiliation: SWOGType of Session: PlenaryBackground The present-day standard of care in the treatment of AIPCA patients consists of the combination of mitoxantrone and prednisone for palliation of disease-related...
What we learned on Monday June 7, 2004 What follows are highlights of the day on Monday June 7th. A more detailed review of selected presentations can be found on OncoLink. BREAST Most of the breast cancer presentations today focused around the issue of Her2/neu. A retrospective...